Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial-Reference-Cited by-同舟云学术

Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial

Published:2022-09-20 Issue: Volume: Page:
ISSN:2688-4887
Container-title:Transgender Health
language:en
Short-container-title:Transgender Health

Author:

Cespedes Michelle S.¹,Das Moupali²^ORCID,Yager Jenna²,Prins Maria³,Krznaric Ivanka⁴,de Jong Jan²^ORCID,Xiao Deqing²^ORCID,Shao Yongwu²,Wong Pamela²,Kintu Alexander²,Carter Christoph²,Hoornenborg Elske⁵,Ruane Peter⁶,Phoenix John⁷,Younis Islam²,Halperin Jason⁸

Affiliation:

1. Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

2. Gilead Sciences, Foster City, California, USA.

3. Department of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers (UMC), University of Amsterdam, Amsterdam, The Netherlands.

4. Zentrum für Infektiologie Berlin Prenzlauer Berg, Berlin, Germany.

5. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.

6. Ruane Clinical Research Group, Inc., Los Angeles, California, USA.

7. Huntridge Family Clinic, Las Vegas, Nevada, USA.

8. Crescent Care, New Orleans, Louisiana, USA.

Publisher

Mary Ann Liebert Inc

Subject

Medicine (miscellaneous),Gender Studies

Link

https://www.liebertpub.com/doi/pdf/10.1089/trgh.2022.0048

Reference35 articles.

1. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis

2. Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM

3. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

4. 6. Sullivan PS, Smith DK, Mera-Giler R, et al. The Impact of Pre-exposure Prophylaxis With FTC/TDF on HIV Diagnoses, 2012–2016, United States. 22nd International AIDS Conference, 23–27 July, Amsterdam, the Netherlands; 2018.

5. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Social, economic, and physical side effects impact PrEP uptake and persistence among transgender women in Peru;BMC Public Health;2024-07-25

2. Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV;British Journal of Clinical Pharmacology;2024-06-12

3. Awareness and utilization of pre-exposure prophylaxis and HIV prevention services among transgender and non-binary adolescent and young adults;Frontiers in Reproductive Health;2024-01-22

4. Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations;Current HIV/AIDS Reports;2023-04-04

5. Inclusion of Transgender and Gender Diverse People in Phase III Trials: Examples from HIV Pharmacologic Prevention Studies;Clinical Pharmacology & Therapeutics;2022-12-21